Skip to main content
. 2015 Jan 28;10(12):2171–2192. doi: 10.4161/auto.36436

Figure 9.

Figure 9.

BafA1 treatment increases the accumulation of SNCA in glial cells in the microenvironment of SNCA-expressing neurons in transgenic mice. Immunohistochemical analysis of glial cells (S100B+) in the microenvironment of SNCA+ neurons within the colliculus and the hippocampus of SNCA-tg mice. (A) SNCA immunoreactivity in glial cells in the colliculus of SNCA-tg mice compared to non-tg mice -/+BafA1 treatment. Insets in the 1st row indicate the region within the superior colliculus which is magnified in the 2nd row. Black arrowheads indicate the presence of SNCA+ neurons based on their morphological appearance in close proximity. Scale bar 1st row 50 μm, 2nd and 3rd row 20 μm. (B) Quantification of glial cells based on their morphology displaying SNCA immunoreactivity in the colliculus of SNCA-tg mice -/+BafA1 treatment. (C) Confocal images of S100B+ astroglia (red) double-labeling for SNCA (green) in close proximity to SNCA+ neurons (N; defined by morphology) in the hippocampus and colliculus of SNCA-tg mice either treated with BafA1 or vehicle. (D) and (E) Quantification of S100B+ and SNCA+ cells after BafA1 treatment in SNCA-tg mice compared to vehicle-treated animals. All values are mean + s.e.m; differences are significant at (#) P < 0.05.